The findings support the increasing amount of data showing that N6LS is a strong antiviral that may be used as part of an all-encompassing antiretroviral treatment plan.
Trial continues as planned to 52 weeks to further characterize the risk-benefit profile.
The researchers created a highly effective conversion technique using mouse cells that can generate over ten neurons from a single skin cell.
The trial achieved its primary endpoint, as previously revealed at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting.
Islatravir, Merck’s investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), inhibits HIV-1 replication through a variety of mechanisms
The current inactivated polio vaccine (IPV), which uses a destroyed form of the poliovirus to trigger an immune system response
At the time of the analysis, less than 25% of the necessary number of events had taken place, indicating that overall survival was not mature.
CagriSema showed a statistically significant and superior weight loss at week 68 compared to placebo, meeting the trial’s primary aim.
The Phase 3 VENTURA research study, which was assessing aticaprant as an adjunctive treatment for major depressive disorder (aMDD), has been discontinued by Johnson & Johnson because of its lack of effectiveness in the target patient population. No new safety signals were found, and the results verified that aticaprant is […]
The study merely demonstrates a connection rather than proving that painkillers enhance concussion recovery.
